Resetting cancer stem cell regulatory nodes upon MYC inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Stem Cell Research

Background:

• MYC deregulation is prevalent in human cancers, driving aggressive cancer stem cell populations.
• MYC's precise role in cancer stem cells and glioblastoma remains incompletely understood.
• Glioblastoma is the most lethal brain tumor, necessitating novel therapeutic targets.

Purpose of the Study:

• To investigate MYC function in glioblastoma stem cells using Omomyc, a MYC-inhibiting polypeptide.
• To elucidate how Omomyc affects cancer stem cell features and the tumor microenvironment.
• To explore Omomyc's molecular mechanisms, including genomic association and target gene regulation.

Main Methods:

• Inducible expression of Omomyc in a glioblastoma model.
• Analysis of cancer stem cell features and tumor microenvironment.
• Assessment of MYC localization and genomic association of Omomyc.
• Transcriptional profiling of key glioblastoma identity and tumor suppressor genes.
• MicroRNA expression analysis.

Main Results:

• Omomyc effectively bridled key cancer stem-like cell features in glioblastoma.
• Omomyc inhibited angiogenesis by affecting the tumor microenvironment.
• Omomyc selectively repressed master transcription factors (e.g., OLIG2, POU3F2, SOX2) driving glioblastoma stem cell identity.
• Omomyc upregulated tumor suppressors (e.g., ID4, MIAT, PTEN) and modulated microRNAs targeting glioblastoma growth and invasion molecules (e.g., EGFR, ZEB1).

Conclusions:

• MYC acts as a network stabilizer, reinforcing gene expression regulatory nodes that control cell phenotype.
• Omomyc demonstrates potential as a therapeutic agent for targeting cancer stem cells, particularly in glioblastoma.
• Targeting MYC activity with Omomyc offers a novel strategy to disrupt glioblastoma stem cell maintenance and tumor progression.